Catalog No.A2001 Synonyms: MDX-010, BMS-734016 For research use only. Not for use in humans.
Ipilimumab is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.
Purity & Quality Control
Choose Selective Immunology & Inflammation related Inhibitors
|Description||Ipilimumab is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.|
Ipilimumab, is a fully humanized IgG1k monoclonal antibody produced by recombinant DNA technology in a CHO mammalian cell expression system, binding with high affinity to the extracellular domain of human (and Cynomolgus monkey) CTLA-4, and acting as an inhibitor of its complex functions. This essentially results in T-cell activation and proliferation, and in lymphocyte infiltration leading to tumor cell death. However, the enhancement of T effector cell function, combined with the inhibition of CD4+ Treg and CD8+ suppressive cell types, are considered essential for mediating the full therapeutic effects of ipilimumab. Ipilimumab can improve ATC proliferation, enhance the BiAb-mediated tumor-specific cytotoxicity, and increase cytokine synthesis, while it attenuates Treg activity as shown by decreased level of IL-10 secretion and reduced Treg population. Ipilimumab and nivolumab treatments could collaboratively enhance effector and memory T cell responses without inappropriately activating naive T cells.
|In vivo||Ipilimumab is shown in phase III clinical trials to have a survival benefit in metastatic melanoma that is durable in 10% to 20% of patients. Conceivably, the main adverse effects of ipilimumab are autoimmunein nature. Ipilimumab enhances antitumor immunity by inhibiting immunosuppressive activity of regulatory T cells (Treg).|
|Storage||Store at -20°C for 2 years. Avoid freeze-thaw cycles.|
If you have any other enquiries, please leave a message.